Nancy E Hynes

Summary

Affiliation: Friedrich Miescher Institute
Country: Switzerland

Publications

  1. doi request reprint Loss of Memo, a novel FGFR regulator, results in reduced lifespan
    Barbara Haenzi
    1Mechanisms of Cancer, Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    FASEB J 28:327-36. 2014
  2. doi request reprint Signalling change: signal transduction through the decades
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, and University of Basel, Basel, Switzerland
    Nat Rev Mol Cell Biol 14:393-8. 2013
  3. doi request reprint The 14-3-3σ tumor suppressor has multiple functions in ErbB2-induced breast cancer
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Cancer Discov 2:19-22. 2012
  4. pmc Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation
    Thomas Schlange
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Breast Cancer Res 9:R63. 2007
  5. doi request reprint PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4059 Basel, Switzerland
    Cancer Cell 15:353-5. 2009
  6. pmc c-Myc affects mRNA translation, cell proliferation and progenitor cell function in the mammary gland
    Tina Stoelzle
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    BMC Biol 7:63. 2009
  7. pmc Key signalling nodes in mammary gland development and cancer: Myc
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Breast Cancer Res 11:210. 2009
  8. pmc Mammary gland growth factors: roles in normal development and in cancer
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Maulbeerestrasse 66, CH 4058 Basel, Switzerland
    Cold Spring Harb Perspect Biol 2:a003186. 2010
  9. doi request reprint Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis
    Julien H Dey
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Cancer Res 70:4151-62. 2010
  10. doi request reprint Memo is a cofilin-interacting protein that influences PLCgamma1 and cofilin activities, and is essential for maintaining directionality during ErbB2-induced tumor-cell migration
    Maria Meira
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    J Cell Sci 122:787-97. 2009

Collaborators

Detail Information

Publications40

  1. doi request reprint Loss of Memo, a novel FGFR regulator, results in reduced lifespan
    Barbara Haenzi
    1Mechanisms of Cancer, Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    FASEB J 28:327-36. 2014
    ..In summary, the results from in vivo and in vitro models support the hypothesis that Memo is a novel regulator of FGFR signaling with a role in controlling 1,25(OH)2D production and normal calcium homeostasis...
  2. doi request reprint Signalling change: signal transduction through the decades
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, and University of Basel, Basel, Switzerland
    Nat Rev Mol Cell Biol 14:393-8. 2013
    ..Here, six researchers reflect on the context in which these discoveries were made, and how our concept of cell signalling has evolved during the past three decades...
  3. doi request reprint The 14-3-3σ tumor suppressor has multiple functions in ErbB2-induced breast cancer
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Cancer Discov 2:19-22. 2012
    ..This study underscores the role of 14-3-3σ as a potent tumor suppressor in ERBB2-driven tumor initiation and progression...
  4. pmc Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation
    Thomas Schlange
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Breast Cancer Res 9:R63. 2007
    ....
  5. doi request reprint PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4059 Basel, Switzerland
    Cancer Cell 15:353-5. 2009
    ..show that trastuzumab disrupts ligand-independent ErbB2/ErbB3/PI3K complexes and blocks AKT signaling; if PI3K is mutated, complex disruption does not inhibit AKT, which explains why trastuzumab is ineffective in some tumors...
  6. pmc c-Myc affects mRNA translation, cell proliferation and progenitor cell function in the mammary gland
    Tina Stoelzle
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    BMC Biol 7:63. 2009
    ..Here we investigated functions of c-Myc during mouse mammary gland development using a conditional knockout approach...
  7. pmc Key signalling nodes in mammary gland development and cancer: Myc
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Breast Cancer Res 11:210. 2009
    ..This review will concentrate on Myc as a signaling mediator in the mammary gland, discussing its regulation and function during normal development, as well as its activation and roles in breast cancer...
  8. pmc Mammary gland growth factors: roles in normal development and in cancer
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Maulbeerestrasse 66, CH 4058 Basel, Switzerland
    Cold Spring Harb Perspect Biol 2:a003186. 2010
    ..We will discuss different peptides in the context of normal development and cancer in this review...
  9. doi request reprint Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis
    Julien H Dey
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Cancer Res 70:4151-62. 2010
    ..Of interest are the downregulated matrix metalloproteases (MMP), in particular MMP9, which is essential for metastatic spread of 4T1 tumors...
  10. doi request reprint Memo is a cofilin-interacting protein that influences PLCgamma1 and cofilin activities, and is essential for maintaining directionality during ErbB2-induced tumor-cell migration
    Maria Meira
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    J Cell Sci 122:787-97. 2009
    ..In summary, these data indicate that Memo also regulates actin dynamics by interacting with cofilin and enhancing its function...
  11. pmc WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth
    Yutaka Matsuda
    Friedrich Miescher Institute for Biomedical Research Part of the Novartis Research Foundation, Basel, Switzerland
    Breast Cancer Res 11:R32. 2009
    ..Here we examine the role of WNT signaling in breast tumor cell migration and on xenograft outgrowth...
  12. doi request reprint Wnt3a regulates proliferation and migration of HUVEC via canonical and non-canonical Wnt signaling pathways
    Ivana Samarzija
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Biochem Biophys Res Commun 386:449-54. 2009
    ..Taken together, our data indicate that Wnt3a induces canonical and non-canonical Wnt signaling in HUVECs, and stimulates their proliferation and migration...
  13. pmc Novel c-MYC target genes mediate differential effects on cell proliferation and migration
    David Cappellen
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    EMBO Rep 8:70-6. 2007
    ..Our combined genomic and phenotypic analysis indicates that c-MYC functions are cellular-context-dependent and that selectively regulated genes are responsible for its differential properties...
  14. ncbi request reprint The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides
    Andrea B Motoyama
    Friedrich Miescher Institute, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Cancer Res 62:3151-8. 2002
    ....
  15. ncbi request reprint TEL/ETV6 is a signal transducer and activator of transcription 3 (Stat3)-induced repressor of Stat3 activity
    Nicole Schick
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, Basel CH 4058, Switzerland
    J Biol Chem 279:38787-96. 2004
    ..Intriguingly, Stat3 repression did not require TEL DNA binding and appeared to proceed via recruitment of TEL to Stat3. Inhibition of Stat3 activity by TEL represents a novel mechanism regulating the Stat3 signaling pathway...
  16. ncbi request reprint Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins
    Magdalena Koziczak
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Oncogene 23:3501-8. 2004
    ..In SUM 52 cells, both MAPK and PI3K signaling pathways were suppressed. In conclusion, results shown here describe a mechanism by which FGFR promotes proliferation of breast cancer cells...
  17. doi request reprint The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression
    Bérengère Fayard
    Friedrich Miescher Institute for Biological Research, Basel, Switzerland
    Cancer Res 69:5690-8. 2009
    ..These results suggest that PN-1 might become a prognostic marker in breast cancer...
  18. doi request reprint ErbB receptors and signaling pathways in cancer
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Curr Opin Cell Biol 21:177-84. 2009
    ..Finally, mechanisms contributing to resistance to ErbB-targeted therapeutics will also be discussed...
  19. ncbi request reprint Memo mediates ErbB2-driven cell motility
    Romina Marone
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Nat Cell Biol 6:515-22. 2004
    ..Our data suggest that Memo controls cell migration by relaying extracellular chemotactic signals to the microtubule cytoskeleton...
  20. doi request reprint The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer
    Anne Boulay
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Cancer Res 68:3743-51. 2008
    ..In summary, we showed that Ret is a novel proliferative pathway interacting with ER signaling in vitro. Expression of Ret in primary breast tumors suggests that Ret might be a novel therapeutic target in breast cancer...
  21. ncbi request reprint Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation
    Magdalena Koziczak
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, 4058 Basel, Switzerland
    J Biol Chem 279:50004-11. 2004
    ..Thus, we propose a novel mechanism for controlling cyclin D1 expression downstream of combined activity of ErbB2 and FGFR-4 that involves S6K1-mediated translation...
  22. pmc Beta1 integrins regulate mammary gland proliferation and maintain the integrity of mammary alveoli
    Na Li
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    EMBO J 24:1942-53. 2005
    ..A connection between p21 Cip1 and beta1 integrin as well as FAK was also established in primary mammary cells. These results point to the essential role of beta1 integrin signaling in mammary epithelial cell proliferation...
  23. doi request reprint Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics
    Patrizia Sini
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Cancer Res 68:1581-92. 2008
    ....
  24. ncbi request reprint Targeting ADAMS and ERBBs in lung cancer
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Cancer Cell 10:7-11. 2006
    ..This minireview will discuss recent findings on possible mechanisms leading to ERBB-targeted therapy resistance and potential means to overcome them...
  25. ncbi request reprint ERBB receptors and cancer: the complexity of targeted inhibitors
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Nat Rev Cancer 5:341-54. 2005
    ..We will discuss the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response...
  26. pmc BAD: a good therapeutic target?
    Andrea B Motoyama
    Friedrich Miescher Institute, Basel, Switzerland
    Breast Cancer Res 5:27-30. 2003
    ..Furthermore, they showed that the major effector of the EGFR-targeted therapy is BAD, a widely expressed BCL-2 family member. These results are promising in light of the role of the EGFR in breast cancer development...
  27. ncbi request reprint Targeting ERBB receptors in cancer
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Recent Results Cancer Res 172:45-57. 2007
  28. ncbi request reprint ErbB receptors: directing key signaling networks throughout life
    Thomas Holbro
    Friedrich Miescher Institute for Biomedical Research, 4002 Basel, Switzerland
    Annu Rev Pharmacol Toxicol 44:195-217. 2004
    ..In this review, we discuss these data in more detail, illustrating the importance of tightly regulated ErbB signaling throughout life...
  29. ncbi request reprint The ErbB receptors and their role in cancer progression
    Thomas Holbro
    Friedrich Miescher Institute, PO Box 2543, 4002, Basel, Switzerland
    Exp Cell Res 284:99-110. 2003
    ..e., ErbB1 cooperates with other classes of receptors, and the ligand-less ErbB2 functions as a heterodimer with other ErbBs...
  30. ncbi request reprint The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade
    Patrizia Sini
    Novartis Institute for Biomedical Research, Oncology Research, Basel, Switzerland
    Clin Cancer Res 11:4521-32. 2005
    ....
  31. ncbi request reprint P-Rex1, a Guanine Exchange Factor that Is Overexpressed in Breast Cancer, Is a Convergence Node for ErbB and CXCR4 Signaling
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Mol Cell 41:5-7. 2011
    ..2010) show that P-Rex1, a Rac1 GEF, is overexpressed in ER+ and/or ErbB2+ breast cancers, suggesting that P-Rex1 might be a convergence node downstream of these receptors and an attractive therapeutic target...
  32. doi request reprint Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets
    Simon Wöhrle
    Novartis Institutes for BioMedical Research, Basel, Switzerland
    J Bone Miner Res 28:899-911. 2013
    ..We therefore propose NVP-BGJ398 treatment as a novel approach for the therapy of FGF23-mediated hypophosphatemic diseases...
  33. ncbi request reprint Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4
    Gertraud Orend
    Friedrich Miescher Institute for Biomedical Research, Novartis Forschungsstiftung, PO Box 2543, CH 4002 Basel, Switzerland
    Oncogene 22:3917-26. 2003
    ..We therefore propose that syndecan-4 signaling plays a central role in the control of cellular proliferation of anchorage-dependent fibroblasts...
  34. doi request reprint Potential for targeting the fibroblast growth factor receptors in breast cancer
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Cancer Res 70:5199-202. 2010
    ..Finally, to improve the chances for success with FGFR signal transduction inhibitors, strategies to choose appropriate breast cancer patients for treatment will be discussed...
  35. pmc MHO1, an evolutionarily conserved gene, is synthetic lethal with PLC1; Mho1p has a role in invasive growth
    Ivan D Schlatter
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    PLoS ONE 7:e32501. 2012
    ..Moreover, a role for Memo in cell motility/invasion appears to be conserved across species...
  36. pmc Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells
    Gianluca Civenni
    Friedrich Miescher Institute, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    EMBO Rep 4:166-71. 2003
    ..Our finding that Wnts transactivate ErbB1 in addition to stimulating the prototypic beta-catenin/TCF pathway may help to explain why wnt1 is a potent oncogene in the mammary gland...
  37. ncbi request reprint The mTOR pathway in breast cancer
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    J Mammary Gland Biol Neoplasia 11:53-61. 2006
    ....
  38. doi request reprint FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone
    Simon Wöhrle
    Novartis Institutes for BioMedical Research, Disease Area Oncology, Basel, Switzerland
    J Bone Miner Res 26:2486-97. 2011
    ..Further, we reveal FGFR signaling as a novel in vivo control mechanism for Fgf23 expression in bone, suggesting a dual function of FGFRs in the FGF-23/Klotho pathway leading to vitamin D and phosphate homeostasis...
  39. pmc Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells
    Albana Gattelli
    Friedrich Miescher Institute for Biomedical Research FMI, Basel, Switzerland
    EMBO Mol Med 5:1335-50. 2013
    ..Our results suggest that Ret kinase should be considered as a novel therapeutic target in subsets of breast cancer. ..
  40. ncbi request reprint Therapeutic targeting of signal transduction pathways and proteins in breast cancer
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    J Mammary Gland Biol Neoplasia 11:1-2. 2006